Holen Sie sich die Stockscreener-App
135.19
4.86%
6.26
Handel nachbörslich:
135.50
0.31
+0.23%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
White Lighthouse Investment Management Inc. Purchases New Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Aigen Investment Management LP Buys Shares of 14,365 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know - TradingView
Biogen Inc. (NASDAQ:BIIB) Receives $185.63 Consensus PT from Brokerages - MarketBeat
Why Is Biogen Stock Climbing Wednesday?Biogen (NASDAQ:BIIB) - Benzinga
Biogen’s Felzartamab Trial: A Potential Game-Changer for Kidney Transplant Treatments - TipRanks
Rituxan Market Size to 2025: Emerging Demands, Trends, - openPR.com
Biogen Asserts No Obligation to Pay $122M in Intellectual Property Royalties Following Mistrial - USA Herald
5 Revealing Analyst Questions From Biogen’s Q2 Earnings Call - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Motley Fool Asset Management LLC - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Invesco Ltd. - MarketBeat
Mizuho Securities USA LLC Reduces Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Acquires 27,734 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
LPL Financial LLC Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Ontario Teachers Pension Plan Board Buys Shares of 10,849 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Says It Owes Nothing After $122M IP Royalties Mistrial - Law360
Sector Update: Health Care - MarketScreener
Biogen CEO Sees Potential in Combining Alzheimer's, Obesity Drugs - MarketScreener
Biogen’s PREVAIL Study: A New Hope for IgA Nephropathy Treatment? - TipRanks
Biogen Sees Potential in Combining Alzheimer’s and Obesity Drugs - Bloomberg.com
Entropy Technologies LP Sells 17,087 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
National Bank of Canada FI Has $27.58 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Charles Schwab Investment Management Inc. Buys 47,956 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wolfe Research Issues Negative Estimate for Biogen Earnings - MarketBeat
Headlands Technologies LLC Cuts Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment - TipRanks
Biogen Faces Growing Pains Even As Its Pipeline Progresses - Finimize
FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More - BioSpace
Biogen, Stoke dose first patient in phase 3 Dravet syndrome trial - Investing.com Australia
Biogen and Stoke Therapeutics Announce First Patient Dosed - GlobeNewswire
Breakthrough Dravet Syndrome Drug Could Transform Treatment: Phase 3 Trial Launches - Stock Titan
Deutsche Bank AG Sells 228,518 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen to invest additional $2B in North Carolina’s Research Triangle Park - MSN
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Primecap Management Co. CA - MarketBeat
iA Global Asset Management Inc. Buys 2,636 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Can Biogen Inc. be recession proofSmart Allocation Stock Ideas - thegnnews.com
Biogen Inc. (NASDAQ:BIIB) Stock Holdings Raised by Natixis Advisors LLC - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Increases Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Koss Olinger Consulting LLC Acquires New Shares in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Will Biogen’s (BIIB) New Lecanemab Data and Earnings Shift Its Alzheimer’s Growth Narrative? - simplywall.st
Vanguard Group Inc. Buys 283,964 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Bank of Nova Scotia Sells 4,241 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Eli Lilly’s obesity pill data; This week’s Q2 highlights; Biogen’s latest reinvention; and more - Endpoints News
J. Safra Sarasin Holding AG Decreases Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Innovative Approach to SMA Treatment: ThecaFlex DRx™ System Study Update - TipRanks
Biogen’s PIERRE-PK Study: A New Approach to Nusinersen Delivery in SMA - TipRanks
Arkadios Wealth Advisors Acquires New Shares in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Acute Ischemic Stroke Pipeline 2025: Latest FDA Approvals, - openPR.com
FY2025 EPS Estimates for Biogen Lifted by Cantor Fitzgerald - MarketBeat
Research Analysts Offer Predictions for Biogen Q3 Earnings - MarketBeat
Eli Lilly And Biogen (And Eisai): Muddying The Waters In Alzheimer's Disease - Seeking Alpha
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment? - TipRanks
We Think Biogen's (NASDAQ:BIIB) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):